Therefore, mAb monalizumab increases the cytotoxic activity of NK and T CD8+ cells by blocking the binding of NKG2A/CD94 to HLA-E, which is typically stimulated by anti-tumor activity and Interferon-gamma (IFN-γ) [55]. The gene discussed is CD8A; the disease is neoplasm.